Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Christian Schneeweis

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5035061317. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
74
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 5 papers · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 17

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70794↗
  2. Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer. First author DOI 10.1053/j.gastro.2025.08.018↗
  3. Cross-species single-cell atlases chart progression, therapy-driven remodelling and immune evasion in pancreatic cancer Co-author DOI 10.64898/2026.03.19.712924↗
  4. KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Co-author DOI 10.1002/1878-0261.13725↗
  5. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41551-024-01273-9↗
  6. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
  7. Identification of the unfolded protein response pathway as target for radiosensitization in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2023.110059↗
  8. NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-022-05535-9↗
  9. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Co-author DOI 10.1002/cac2.12280↗
  10. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Co-author DOI 10.1007/s00018-022-04638-y↗
  11. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Co-author DOI 10.1038/s43018-021-00326-1↗
  12. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  13. RelA Is an Essential Target for Enhancing Cellular Responses to the DNA Repair/Ref-1 Redox Signaling Protein and Restoring Perturbated Cellular Redox Homeostas… Co-author DOI 10.3389/fonc.2022.826617↗
  14. The SUMO pathway in pancreatic cancer: insights and inhibition. Co-author DOI 10.1038/s41416-020-01119-6↗
  15. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Co-author DOI 10.1002/1878-0261.12835↗
  16. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Co-author DOI 10.1136/gutjnl-2018-317856↗
  17. MTOR inhibitor-based combination therapies for pancreatic cancer. First author DOI 10.1038/bjc.2017.421↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Günter Schneider · 16 shared papers, 2018–2026 · strength 2.35
  2. Dieter Saur · 13 shared papers, 2018–2026 · strength 1.77
  3. Roland Rad · 11 shared papers, 2018–2026 · strength 1.40
  4. Maximilian Reichert · 11 shared papers, 2018–2026 · strength 1.36
  5. Matthias Wirth · 10 shared papers, 2018–2026 · strength 1.31
  6. Zonera Hassan · 8 shared papers, 2018–2022 · strength 0.93
  7. Lukas Krauß · 6 shared papers, 2022–2026 · strength 0.86
  8. Carolin Schneider · 6 shared papers, 2022–2026 · strength 0.86
  9. Elisabeth Heßmann · 5 shared papers, 2022–2026 · strength 0.83
  10. Roland Michael Schmid · 5 shared papers, 2018–2026 · strength 0.76
  11. Ulrich Bernd Keller · 5 shared papers, 2020–2026 · strength 0.75
  12. Michael B. Ghadimi · 4 shared papers, 2024–2026 · strength 0.71
  13. Constanza Tapia Contreras · 4 shared papers, 2024–2026 · strength 0.71
  14. Felix Orben · 5 shared papers, 2020–2026 · strength 0.65
  15. Marian Grade · 4 shared papers, 2022–2026 · strength 0.62
  16. Oliver Holger Krämer · 5 shared papers, 2018–2026 · strength 0.60
  17. Chiara Falcomatà · 4 shared papers, 2022–2026 · strength 0.57
  18. Volker Ellenrieder · 3 shared papers, 2024–2026 · strength 0.50
  19. Stefanie Bärthel · 3 shared papers, 2022–2026 · strength 0.46
  20. Hazal Köse · 2 shared papers, 2026 · strength 0.40
  21. Sophie Dobiasch · 2 shared papers, 2024–2025 · strength 0.40
  22. Stephanie Elisabeth Combs · 2 shared papers, 2024–2025 · strength 0.40
  23. Alexander Arlt · 3 shared papers, 2018–2023 · strength 0.35
  24. Bernhard Küster · 3 shared papers, 2022–2024 · strength 0.35
  25. Sebastian Mueller · 2 shared papers, 2025–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.